Novel CAR-ITNK Cells Targeting CD70 and CLL1 therapy (Tongji Hospital)

N/A

Report date: 2026/02/28 20:00:37

Base Information

Drug NameNovel CAR-ITNK Cells Targeting CD70 and CLL1 therapy (Tongji Hospital)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionNatural killer cell replacementsCD70 antigen modulatorsC-Type lectin domain family 12 member A modulators

TargetsCD70 antigenC-Type lectin domain family 12 member A

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesTongji Hospital

China Registration ClassN/A

Develop Information

Active CompaniesTongji Hospital

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A